2026年11月5日星期四
M
Wereldwijde Kroniek
Wereldwijd nieuws
Japan's Yamato targets 'leaner' delivery service in push for profit: president— 日经 Nikkei AsiaToyota to bring Celica back to premier rally racing after 32-year break— 日经 Nikkei AsiaU.S. Steel grows to 40% of Nippon Steel profit as prices surge— 日经 Nikkei AsiaThe price of building Japanese stealth frigates in Australia— 日经 Nikkei AsiaMcDonald's wages war on KFC in Japan as consumers crave chicken— 日经 Nikkei AsiaJapan's Koito looks to keep lighting way with smart automotive lamps— 日经 Nikkei AsiaAnalysis: How a secret feud ignited Xi Jinping's governance drive— 日经 Nikkei AsiaJapan lender leads $600m credit line to help Malaysia's Petronas cut CO2— 日经 Nikkei AsiaJapan's Yamato targets 'leaner' delivery service in push for profit: president— 日经 Nikkei AsiaToyota to bring Celica back to premier rally racing after 32-year break— 日经 Nikkei AsiaU.S. Steel grows to 40% of Nippon Steel profit as prices surge— 日经 Nikkei AsiaThe price of building Japanese stealth frigates in Australia— 日经 Nikkei AsiaMcDonald's wages war on KFC in Japan as consumers crave chicken— 日经 Nikkei AsiaJapan's Koito looks to keep lighting way with smart automotive lamps— 日经 Nikkei AsiaAnalysis: How a secret feud ignited Xi Jinping's governance drive— 日经 Nikkei AsiaJapan lender leads $600m credit line to help Malaysia's Petronas cut CO2— 日经 Nikkei Asia

Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial

Bron Nature 生命科学1 dagen geleden
Samenvatting van de inhoud

Deze site biedt alleen een index van titels en samenvattingen. De volledige inhoud en het auteursrecht behoren toe aan de oorspronkelijke uitgever. Klik op de originele link om te lezen.

Ga naar het origineel
Behorend kanaal
Wetenschap
Behorende regio
Wereldwijd perspectief
Taal van het origineel
English
Itemnummer
science-f81c0280

Comments 0 comments

No comments yet. Be the first.

Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial · Wereldwijde Kroniek